Prophylactic Use of Macrolide Antibiotics for the Prevention of Chronic Obstructive Pulmonary Disease Exacerbation: A Meta-Analysis

Abstract

BackgroundAcute exacerbations of chronic obstructive pulmonary disease (AECOPDs) can lead to high frequencies and rates of hospitalization and mortality. Macrolides are a class of antibiotics that possess both antimicrobial and anti-inflammatory properties. Since the occurrence of AECOPDs is associated with aggravation of airway inflammation and bacterial infections, prophylactic macrolide treatment may be an effective approach towards the prevention of AECOPDs.MethodsWe systemically searched the PubMed, Embase and Cochrane Library databases to identify randomized controlled trials (RCTs) that evaluated the effect of prophylactic macrolide therapy on the prevention of AECOPDs. The primary outcomes were the total number of patients with one or more exacerbations as well as the rate of exacerbations per patient per year.ResultsNine RCTs comprising 1666 patients met the inclusion criteria. Pooled evidence showed macrolides could reduce the frequency of exacerbations in patients with COPD by both unweighted (RR = 0.70; 95% CI: 0.56–0.87; P < 0.01) and weighted approaches (RR = 0.58, 95% CI: 0.43–0.78, P < 0.01). Subgroup analysis showed only 6–12 months of erythromycin or azithromycin therapy could be effective. Moreover, among studies with 6–12 months of azithromycin therapy, both the daily dosing regimen and the intermittent regimen significantly reduced exacerbation rates. The overall number of hospitalizations and the all-cause rate of death were not significantly different between the treatment and control groups. A tendency for more adverse events was found in the treatment groups (OR = 1.55, 95%CI: 1.003–2.39, P = 0.049).ConclusionsOur results suggest 6-12 months erythromycin or azithromycin therapy could effectively reduce the frequency of exacerbations in patients with COPD. However, Long-term treatment may bring increased adverse events and the emergence of macrolide-resistance. A recommendation for the prophylactic use of macrolide therapy should weigh both the advantages and disadvantages.

The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia

“…Their beneficial effect in chronic inflammatory lung diseases such as diffuse panbronchiolitis [26], cystic fibrosis [27], bronchiectasis [28], bronchiolitis obliterans syndrome [29], asthma [30], and COPD [31] are well documented. However, their benefit in the setting of acute pulmonary inflammation, as in CAP, is not as well established.…”

Evaluation and Exploration on the Effect of the Management of Chronic Obstructive Pulmonary Disease in Rural Areas through an Internet-Based Network Consulting Room

“…Continuous management of COPD patients after discharge is very important [11]. Correct drug treatment can relieve the symptoms of COPD patients [12] and reduce the risk and frequency of acute attacks [13]. Furthermore, it can improve the health and exercise tolerance of patients [14].…”

COPD Guidelines: Old Gold versus New Gold

“…20,21 The 2017 GOLD guidelines go further in advising physicians exactly what class of medication to use, in which COPD patients according to where they fall in the ABCD grading scheme:…”